Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11731340 | 0.89 | MAPT (0.48) | IL1BTNFNLRP3GAAMAPT | |
| SCHEMBL5756006 | 0.87 | IL1B (0.53) | IL1BTNFNLRP3GAAALDH1A1 | |
| SCHEMBL5884486 | 0.85 | MAPT (0.46) | IL1BTNFNLRP3GAAMAPT | |
| Hydrochloric Acid SCHEMBL5756281 | 0.85 | IL1B (0.51) | IL1BTNFNLRP3GAAALDH1A1 | |
| SCHEMBL6702206 | 0.80 | MAPT (0.55) | IL1BTNFNLRP3GAAMAPT | |
| SCHEMBL5676891 | 0.78 | MAPT (0.49) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL3641438 | 0.77 | MAPT (0.48) | GAAMAPTALDH1A1KDM4EHTR1A | |
| SCHEMBL6861106 | 0.77 | MAPT (0.52) | GAAMAPTALDH1A1POLBKDM4E | |
| SCHEMBL11726472 | 0.77 | MAPT (0.44) | IL1BTNFNLRP3GAAMAPT | |
| SCHEMBL10533786 | 0.76 | IL1B (0.45) | IL1BTNFNLRP3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | IL1B 3640/4885TNF 3142/4885NLRP3 969/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | IL1B 836/4885TNF 772/4885NLRP3 159/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.